Industry Theater – American Thoracic Society 2018, May 18–23.
During this Novartis supported Industry Theater, a faculty of experts discuss the new evidence informing the role of LABA/LAMA and LABA/LAMA/ICS therapy in COPD management. The importance of personalized COPD management is discussed, including clinical considerations and consensus regarding use of ICS, and evidence-based approaches for ICS withdrawal.
This Novartis sponsored programme is only available to non-US attendees.
Professor Singh reviews current GOLD recommendations and the supporting evidence for LABA/LAMA treatment and ICS withdrawal in appropriate patients.
Professor Chapman presents the SUNSET study rationale, design and results.
Professor Singh reviews key data from recent clinical trials comparing ICS/LABA/LAMAs with LABA/LAMAs, and the implications for COPD management.
The SUNSET study – introductory video and publication summary: 'Long-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trial.'
Alternatively login via
Back to epgonline.org